Achiko AG Announces Corporate Update Webcast
November 16, 2022 10:38 ET
|
Achiko AG
ZURICH, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare technology company that is developing new...
Achiko AG Commences Commercial Deliveries in Indonesia
November 14, 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) is proud to...
Achiko AG Production and Company Update
November 02, 2022 07:34 ET
|
Achiko AG
Completing Production Pilot for Generation 2 of AptameX™ as a Precursor to Mass Commercial ProductionExpect to Commence Delivery to Sales and Marketing Contract with Nahdlatul Ulama on Commencement of...
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
October 27, 2022 09:04 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für COMIRNATY® für Kinder im Alter von 6 Monaten bis unter 5 Jahren in der Europäischen Union
October 19, 2022 11:45 ET
|
BioNTech SE
NEW YORK und MAINZ, Deutschland, 19. Oktober 2022 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel...
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
October 19, 2022 11:45 ET
|
BioNTech SE
NEW YORK and MAINZ, Germany, October 19, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for...
Achiko AG Appoints New Chief Financial Officer
October 07, 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare...
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
October 04, 2022 08:45 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Achiko AG Reports First Half to June 30, 2022 Results and Provides Corporate Update as of September 30, 2022
October 03, 2022 07:33 ET
|
Achiko AG
Achiko reports an EBITDA loss of USD $1.9 million, compared to an EBITDA loss of USD $4.6 million for the six months ending June 30, 2021.Focal points of the first half year were completion of a major...
Dyadic Updates Market on Recent Scientific Achievements
September 13, 2022 08:00 ET
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...